The DOI matches its Crossref record; 66 of the 66 references it cites were found in a registry or an index.
Bad Bugs, No Drugs: No ESKAPE! An Update from the Infectious Diseases Society of America
Abstract
The Infectious Diseases Society of America (IDSA) continues to view with concern the lean pipeline for novel therapeutics to treat drug-resistant infections, especially those caused by gram-negative pathogens. Infections now occur that are resistant to all current antibacterial options. Although the IDSA is encouraged by the prospect of success for some agents currently in preclinical development, there is an urgent, immediate need for new agents with activity against these panresistant organisms. There is no evidence that this need will be met in the foreseeable future. Furthermore, we remain concerned that the infrastructure for discovering and developing new antibacterials continues to stagnate, thereby risking the future pipeline of antibacterial drugs. The IDSA proposed solutions in its 2004 policy report, "Bad Bugs, No Drugs: As Antibiotic R&D Stagnates, a Public Health Crisis Brews," and recently issued a "Call to Action" to provide an update on the scope of the problem and the proposed solutions. A primary objective of these periodic reports is to encourage a community and legislative response to establish greater financial parity between the antimicrobial development and the development of other drugs. Although recent actions of the Food and Drug Administration and the 110th US Congress present a glimmer of hope, significant uncertainly remains. Now, more than ever, it is essential to create a robust and sustainable antibacterial research and development infrastructure--one that can respond to current antibacterial resistance now and anticipate evolving resistance. This challenge requires that industry, academia, the National Institutes of Health, the Food and Drug Administration, the Centers for Disease Control and Prevention, the US Department of Defense, and the new Biomedical Advanced Research and Development Authority at the Department of Health and Human Services work productively together. This report provides an update on potentially effective antibacterial drugs in the late-stage development pipeline, in the hope of encouraging such collaborative action.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Wisplinghoff, H., Bischoff, T., Tallent, S. M., Seifert, H., Wenzel, R. P., & Edmond, M. B. (2004) · Clinical Infectious Diseases · doi:10.1086/421946 · Cited by 4,496
Extended-Spectrum β-Lactamases: a Clinical Update
Paterson, D. L., & Bonomo, R. A. (2005) · Clinical Microbiology Reviews · doi:10.1128/cmr.18.4.657-686.2005 · Cited by 3,491
System, A. R. F. T. N. (2003) · American Journal of Infection Control · doi:10.1016/j.ajic.2003.09.002 · Cited by 2,915
System, A. R. F. T. N. (2004) · American Journal of Infection Control · doi:10.1016/j.ajic.2004.10.001 · Cited by 2,342
Federal Funding for the Study of Antimicrobial Resistance in Nosocomial Pathogens: No ESKAPE
Rice, L. B. (2008) · The Journal of Infectious Diseases · doi:10.1086/533452 · Cited by 2,310
Self-citationExtended-spectrum β-lactamase-producing Enterobacteriaceae: an emerging public-health concern
Pitout, J. D., & Laupland, K. B. (2008) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(08)70041-0 · Cited by 2,044
Falagas, M. E., Kasiakou, S. K., & Saravolatz, L. D. (2005) · Clinical Infectious Diseases · doi:10.1086/429323 · Cited by 1,744
Spellberg, B., Guidos, R., Gilbert, D., Bradley, J., Boucher, H. W., Scheld, W. M., Bartlett, J. G., Edwards, J., & the Infectious Diseases Society of America (2008) · Clinical Infectious Diseases · doi:10.1086/524891 · Cited by 1,642
Self-citationNosocomial Bloodstream Infections in United States Hospitals: A Three‐Year Analysis
Edmond, M. B., Wallace, S. E., McClish, D. K., Pfaller, M. A., Jones, R. N., & Wenzel, R. P. (1999) · Clinical Infectious Diseases · doi:10.1086/520192 · Cited by 1,387
Global Challenge of Multidrug-Resistant Acinetobacter baumannii
Perez, F., Hujer, A. M., Hujer, K. M., Decker, B. K., Rather, P. N., & Bonomo, R. A. (2007) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01464-06 · Cited by 1,139
Talbot, G. H., Bradley, J., Edwards, J. E., Gilbert, D., Scheld, M., & Bartlett, J. G. (2006) · Clinical Infectious Diseases · doi:10.1086/499819 · Cited by 1,104
Self-citationLinezolid resistance in a clinical isolate of Staphylococcus aureus
Tsiodras, S., Gold, H. S., Sakoulas, G., Eliopoulos, G. M., Wennersten, C., Venkataraman, L., Moellering, R. C., & Ferraro, M. J. (2001) · The Lancet · doi:10.1016/s0140-6736(01)05410-1 · Cited by 1,033
Maragakis, L. L., & Perl, T. M. (2008) · Clinical Infectious Diseases · doi:10.1086/529198 · Cited by 969
Trends in antimicrobial drug development: Implications for the future
Spellberg, B., Powers, J. H., Brass, E. P., Miller, L. G., & Edwards, J. E. (2004) · Clinical Infectious Diseases · doi:10.1086/420937 · Cited by 867
Self-citationEpidemiology of Methicillin‐Resistant Staphylococcus aureus
Boucher, H. W., & Corey, G. R. (2008) · Clinical Infectious Diseases · doi:10.1086/533590 · Cited by 805
Self-citationJacoby, G. A., & Munoz-Price, L. S. (2005) · New England Journal of Medicine · doi:10.1056/nejmra041359 · Cited by 787
Munoz-Price, L. S., & Weinstein, R. A. (2008) · New England Journal of Medicine · doi:10.1056/nejmra070741 · Cited by 772
Taubes, G. (2008) · Science · doi:10.1126/science.321.5887.356 · Cited by 751
Emerging carbapenemases in Gram-negative aerobes
Nordmann, P., & Poirel, L. (2002) · Clinical Microbiology and Infection · doi:10.1046/j.1469-0691.2002.00401.x · Cited by 684
Neuhauser, M. M., Weinstein, R. A., Rydman, R., Danziger, L. H., Karam, G., & Quinn, J. P. (2003) · JAMA · doi:10.1001/jama.289.7.885 · Cited by 678
Schwaber, M. J., & Carmeli, Y. (2007) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkm318 · Cited by 626
Clinical and Economic Impact of Common Multidrug-Resistant Gram-Negative Bacilli
Giske, C. G., Monnet, D. L., Cars, O., & Carmeli, Y. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01169-07 · Cited by 610
Bratu, S., Landman, D., Haag, R., Recco, R., Eramo, A., Alam, M., & Quale, J. (2005) · Archives of Internal Medicine · doi:10.1001/archinte.165.12.1430 · Cited by 573
Klevens, R. M., Edwards, J. R., Tenover, F. C., McDonald, L. C., Horan, T., Gaynes, R., & System, N. N. I. S. (2006) · Clinical Infectious Diseases · doi:10.1086/499367 · Cited by 551
Self-citationThe β-lactamase threat in Enterobacteriaceae, Pseudomonas and Acinetobacter
Livermore, D. M., & Woodford, N. (2006) · Trends in Microbiology · doi:10.1016/j.tim.2006.07.008 · Cited by 510
Bradford, P. A., Bratu, S., Urban, C., Visalli, M., Mariano, N., Landman, D., Rahal, J. J., Brooks, S., Cebular, S., & Quale, J. (2004) · Clinical Infectious Diseases · doi:10.1086/421495 · Cited by 485
Schwaber, M. J., Navon-Venezia, S., Kaye, K. S., Ben-Ami, R., Schwartz, D., & Carmeli, Y. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.50.4.1257-1262.2006 · Cited by 416
Pandrug-resistant Gram-negative bacteria: the dawn of the post-antibiotic era?
Falagas, M. E., & Bliziotis, I. A. (2007) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2006.12.012 · Cited by 393
Bratu, S., Tolaney, P., Karumudi, U., Quale, J., Mooty, M., Nichani, S., & Landman, D. (2005) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dki175 · Cited by 307
Stryjewski, M. E., Graham, D. R., Wilson, S. E., O’Riordan, W., Young, D., Lentnek, A., Ross, D. P., Fowler, V. G., Hopkins, A., Friedland, H. D., et al. (2008) · Clinical Infectious Diseases · doi:10.1086/587896 · Cited by 289
Noel, G. J., Bush, K., Bagchi, P., Ianus, J., & Strauss, R. S. (2008) · Clinical Infectious Diseases · doi:10.1086/526527 · Cited by 270
Stryjewski, M. E., & Chambers, H. F. (2008) · Clinical Infectious Diseases · doi:10.1086/533593 · Cited by 268
Tigecycline Efflux as a Mechanism for Nonsusceptibility in Acinetobacter baumannii
Peleg, A. Y., Adams, J., & Paterson, D. L. (2007) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01198-06 · Cited by 257
Acinetobacter baumannii bloodstream infection while receiving tigecycline: a cautionary report
Peleg, A. Y., Potoski, B. A., Rea, R., Adams, J., Sethi, J., Capitano, B., Husain, S., Kwak, E. J., Bhat, S. V., & Paterson, D. L. (2006) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkl441 · Cited by 248
Chopra, I., Schofield, C., Everett, M., O'Neill, A., Miller, K., Wilcox, M., Frère, J.-M., Dawson, M., Czaplewski, L., Urleb, U., et al. (2008) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(08)70018-5 · Cited by 243
Chastre, J., Wunderink, R., Prokocimer, P., Lee, M., Kaniga, K., & Friedland, I. (2008) · Critical Care Medicine · doi:10.1097/ccm.0b013e3181691b99 · Cited by 237
Seltzer, E., Dorr, M. B., Goldstein, B. P., Perry, M., Dowell, J. A., Henkel, T., & Dalbavancin Skin and Soft-Tissue Infection Study Group (2003) · Clinical Infectious Diseases · doi:10.1086/379015 · Cited by 231
Tigecycline: A New Glycylcycline for Treatment of Serious Infections
Noskin, G. A. (2005) · Clinical Infectious Diseases · doi:10.1086/431672 · Cited by 226
Liu, C., Graber, C. J., Karr, M., Diep, B. A., Basuino, L., Schwartz, B. S., Enright, M. C., O’Hanlon, S. J., Thomas, J. C., Perdreau‐Remington, F., et al. (2008) · Clinical Infectious Diseases · doi:10.1086/587893 · Cited by 205
Peleg, A. Y., Franklin, C., Bell, J. M., & Spelman, D. W. (2005) · Clinical Infectious Diseases · doi:10.1086/497831 · Cited by 190
Perspectives on Daptomycin Resistance, with Emphasis on Resistance in Staphylococcus aureus
Boucher, H. W., & Sakoulas, G. (2007) · Clinical Infectious Diseases · doi:10.1086/520655 · Cited by 174
Self-citationDeshpande, L. M., Jones, R. N., Fritsche, T. R., & Sader, H. S. (2006) · Microbial Drug Resistance · doi:10.1089/mdr.2006.12.223 · Cited by 169
Talbot et al. (2006 42:657-68)
(2006) · Clinical Infectious Diseases · doi:10.1086/503200 · Cited by 166
DeJonge, M. H., Burchfield, D. J., Bloom, B. T., Dueñas, M., Walker, W., Polak, M. J., Jung, E., MILLARD, D. D., Schelonka, R. L., Eyal, F. G., et al. (2007) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2007.04.060 · Cited by 155
Weems, J. J., Steinberg, J. P., Filler, S. G., Baddley, J. W., Corey, G. R., Sampathkumar, P., Winston, L. G., John, J. F., Kubin, C. J., Talwani, R., et al. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00096-06 · Cited by 154
Bishop, E. J., Melvani, S., Howden, B. P., Charles, P. G. P., & Grayson, M. L. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.50.4.1599-1602.2006 · Cited by 146
Consumption of Imipenem Correlates with β-Lactam Resistance in Pseudomonas aeruginosa
Lepper, P. M., Grusa, E., Reichl, H., Högel, J., & Trautmann, M. (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.46.9.2920-2925.2002 · Cited by 144
A Step Closer to Extreme Drug Resistance (XDR) in Gram-Negative Bacilli
Paterson, D. L., & Doi, Y. (2007) · Clinical Infectious Diseases · doi:10.1086/522287 · Cited by 139
Detection of KPC Carbapenem-Hydrolyzing Enzymes in Enterobacter spp. from Brooklyn, New York
Bratu, S., Landman, D., Alam, M., Tolentino, E., & Quale, J. M. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.2.776-778.2005 · Cited by 133
Schlievert, P. M., Case, L. C., Strandberg, K. L., Abrams, B. B., & Leung, D. Y. M. (2008) · Clinical Infectious Diseases · doi:10.1086/586746 · Cited by 124
Bratu, S., Brooks, S., Burney, S. N., Kochar, S., Gupta, J., Landman, D., & Quale, J. M. (2007) · Clinical Infectious Diseases · doi:10.1086/512370 · Cited by 122
Rupp, M. E., Holley, H. P., Lutz, J. E., Dicpinigaitis, P. V., Woods, C. W., Levine, D. P., Veney, N., & Fowler, V. G. (2007) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00570-07 · Cited by 98
Urban, C. M., Bradford, P. A., Tuckman, M., Segal‐Maurer, S., Wehbeh, W., Grenner, L., Colon‐Urban, R., Mariano, N., & Rahal, J. J. (2008) · Clinical Infectious Diseases · doi:10.1086/588048 · Cited by 92
Segreti, J. A., Crank, C. W., & Finney, M. S. (2006) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.26.3.347 · Cited by 88
Fritsche, T. R., Strabala, P., Sader, H. S., Dowzicky, M. J., & Jones, R. N. (2005) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2005.06.010 · Cited by 75
Erlandson, K. M., Sun, J., Iwen, P. C., & Rupp, M. E. (2007) · Clinical Infectious Diseases · doi:10.1086/523588 · Cited by 69
Bloom, B., Schelonka, R., Kueser, T. J., Walker, W. M., Jung, E., Kaufman, D., Kesler, K., Roberson, D., Patti, J., & Hetherington, S. (2005) · The Pediatric Infectious Disease Journal · doi:10.1097/01.inf.0000180504.66437.1f · Cited by 61
In Vitro and In Vivo Antibacterial Activities of CS-023 (RO4908463), a Novel Parenteral Carbapenem
Koga, T., Abe, T., Inoue, H., Takenouchi, T., Kitayama, A., Yoshida, T., Masuda, N., Sugihara, C., Kakuta, M., Nakagawa, M., et al. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.8.3239-3250.2005 · Cited by 52
What is in the pipeline for Gram-negative pathogens?
Talbot, G. H. (2008) · Expert Review of Anti-infective Therapy · doi:10.1586/14787210.6.1.39 · Cited by 51
Self-citationInfectious Diseases Society of America (2008) · Clinical Infectious Diseases · doi:10.1086/591411 · Cited by 48
Lin, Y. C., Chen, T. L., Ju, H. L., Chen, H. S., Wang, F. D., Yu, K. W., & Liu, C. Y. (2006) · PubMed · Cited by 41
Pfaller, M. A., Sader, H. S., Fritsche, T. R., & Jones, R. N. (2006) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2006.02.009 · Cited by 35
Investigational treatments for postoperative surgical site infections
Poulakou, G., & Giamarellou, H. (2007) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.16.2.137 · Cited by 24
Trends in disease focus of drug development
KARLBERG, J. P. E. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2618 · Cited by 24
Spellberg, B. J., Fleming, T. R., & Gilbert, D. N. (2008) · Clinical Infectious Diseases · doi:10.1086/591389 · Cited by 15
Self-citationCannon, J. P., Pachucki, C. T., Aneziokoro, C., & Lentino, J. R. (2006) · Infectious Diseases in Clinical Practice · doi:10.1097/01.idc.0000226868.52136.24 · Cited by 3
Cited by
Magiorakos, A.-P., Srinivasan, A., Carey, R. B., Carmeli, Y., Falagas, M. E., Giske, C. G., Harbarth, S., Hindler, J. F., Kahlmeter, G., Olsson-Liljequist, B., et al. (2012) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2011.03570.x · Cited by 14,449
Self-citationOrigins and evolution of antibiotic resistance
Davies, J., & Davies, D. (2010) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.00016-10 · Cited by 5,784
Antibiotic resistance-the need for global solutions
Laxminarayan, R., Duse, A., Wattal, C., Zaidi, A. K. M., Wertheim, H. F. L., Sumpradit, N., Vlieghe, E., Hara, G. L., Gould, I. M., Goossens, H., et al. (2013) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(13)70318-9 · Cited by 4,439
Kumarasamy, K. K., Toleman, M. A., Walsh, T. R., Bagaria, J., Butt, F., Balakrishnan, R., Chaudhary, U., Doumith, M., Giske, C. G., Irfan, S., et al. (2010) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(10)70143-2 · Cited by 2,922
Klebsiella pneumoniae: Going on the Offense with a Strong Defense
Paczosa, M. K., & Mecsas, J. (2016) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.00078-15 · Cited by 1,988
Metadata
- Authors
- Boucher, H. W., Talbot, G. H., Bradley, J. S., Edwards, J. E., Gilbert, D., Rice, L. B., Scheld, M., Spellberg, B., & Bartlett, J.
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2009-01
- Volume
- 48
- Issue
- 1
- Pages
- 1-12
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- OpenAlex
- W2115486016
- Cited by
- 4,958
- References
- 66
- FWCI
- 162.07
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.